Obesity and novel management of inflammatory bowel disease
作者机构：Department of GastroenterologyCHA Bundang Medical CenterCHA University School of MedicineSeongnam 13496South Korea Department of Biomedical Science and EngineeringGwangju Institute of Science and TechnologyGwangju 62465South Korea Institute of Basic Medical SciencesCHA University School of MedicineSeongnam 13496South Korea
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2023年第29卷第12期
页 面：1779-1794页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Supported by National Research Foundation of Korea grant from the Korean government the Ministry of Science and ICT NRF-2020R1F1A1066323 and NRF-2021R1F1A1061550
主 题：Obesity Inflammatory bowel disease Crohn’s disease Ulcerative colitis
摘 要：Obesity is prevalent within the inflammatory bowel disease(IBD)population,particularly in newly developed *** epidemiological studies have suggested that 15%-40%of IBD patients are obese,and there is a potential role of obesity in the pathogenesis of *** dysfunction of mesenteric fat worsens the inflammatory course of Crohn’s disease and may induce formation of strictures or ***,obesity may affect the disease course or treatment response of *** the increasing data supporting the pathophysiologic and epidemiologic relationship between obesity and IBD,obesity control is being suggested as a novel management for ***,this review aimed to describe the influence of obesity on the outcomes of IBD treatment and to present the current status of pharmacologic or surgical anti-obesity treatments in IBD patients.
维普期刊数据库